Host: |
Mouse |
Applications: |
IHC-P |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Mouse monoclonal antibody anti-Keratin 8/18 is suitable for use in Immunohistochemistry research applications. |
Clonality: |
Monoclonal |
Clone ID: |
B22.1/B23.1 |
Conjugation: |
Unconjugated |
Isotype: |
IgG1/Kappa + IgG1/Kappa |
Formulation: |
Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin |
Purification: |
Affinity purified |
Dilution Range: |
1:100‐200 |
Storage Instruction: |
Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C. |
Gene Symbol: |
KRT8KRT18 |
Gene ID: |
38563875 |
Uniprot ID: |
K2C8_HUMANK1C18_HUMAN |
Specificity: |
Positive control: Skin, breast carcinoma |
Immunogen: |
Cytokeratins purified from breast cancer MCF-7 cells |
Tissue Specificity | P05787 - Observed in muscle fibers accumulating in the costameres of myoplasm at the sarcolemma membrane in structures that contain dystrophin and spectrin. Expressed in gingival mucosa and hard palate of the oral cavity.P05783 - Expressed in colon, placenta, liver and very weakly in exocervix. Increased expression observed in lymph nodes of breast carcinoma. |
Alternative Antibody Names | Anti-Keratin - Type Ii Cytoskeletal 8 antibodyAnti-Cytokeratin-8 antibodyAnti-Ck-8 antibodyAnti-Keratin-8 antibodyAnti-K8 antibodyAnti-Type-Ii Keratin Kb8 antibodyAnti-KRT8 antibodyAnti-CYK8 antibodyAnti-Keratin - Type I Cytoskeletal 18 antibodyAnti-Cell Proliferation-Inducing Gene 46 Protein antibodyAnti-Cytokeratin-18 antibodyAnti-Ck-18 antibodyAnti-Keratin-18 antibodyAnti-K18 antibodyAnti-KRT18 antibodyAnti-CYK18 antibodyAnti-PIG46 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance